Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / IGC Pharma Q2 2026 CALMA Trial Update
Business earnings report

IGC Pharma Q2 2026 CALMA Trial Update

Analysis based on 6 articles · First reported Aug 17, 2026 · Last updated Aug 17, 2026

Sentiment
10
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The announcement of CALMA trial progress and expected Q4 topline data may positively influence IGC Pharma's stock as it de-risks the clinical program. However, the company's limited cash position and ongoing losses could temper investor enthusiasm.

Biotechnology Pharmaceuticals
Event Summary

IGC Pharma, Inc. reported financial results for Q2 2026 and provided an update on its lead Alzheimer's program, IGC-AD1. The Phase 2 CALMA trial reached its 146-patient baseline randomization target and is within six randomizations of enrollment closure, with topline data expected in Q4 2026. Management converted approximately $1.15 million of debt into equity, preserving cash. The company also received authorization in Colombia to conduct psilocybin development activities. Net loss widened to $3.0 million, and cash stood at $331 thousand.

Key Actions
90 IGC Pharma advanced enrollment
50 IGC Pharma converted debt to equity Ram Mukunda
40 IGC Pharma received psilocybin authorization Colombia
30 IGC Pharma reported Q2 results
Entities Involved
stock
IGC Pharma
IGC Pharma is the central entity, reporting Q2 results and advancing its lead Alzheimer's candidate. The trial progress and equity conversion are positive, but financial losses and low cash remain concerns.
Importance 100.0 Sentiment 10.0
per
Ram Mukunda
As CEO, Ram Mukunda provided strategic updates and converted owed amounts into equity, aligning his interests with shareholders and preserving company cash.
Importance 60.0 Sentiment 10.0
cnt
Colombia
Colombia granted IGC Pharma authorization for psilocybin development, enabling potential expansion into neuropsychiatric treatments, though clinical trials require further approvals.
Importance 30.0 Sentiment 5.0
stock
O-Bank Co., Ltd.
O-Bank provides a $12 million revolving credit facility to IGC Pharma, which remains undrawn and serves as a liquidity source.
Importance 20.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.